Oramed Pharmaceuticals Inc. (ORMP) Earnings History
Profitable23 years of earnings data (2003–2025) · Positive TTM net income
Loading earnings history...
Oramed Pharmaceuticals Inc. (ORMP) Earnings Overview
As of June 23, 2026, Oramed Pharmaceuticals Inc. (ORMP) reported trailing twelve-month net income of $110M, reflecting +419.1% year-over-year growth. The company earned $2.62 per diluted share over the past four quarters, with a net profit margin of 3202.5%.
Looking at the long-term picture, ORMP's historical earnings data spans multiple years. The company achieved its highest annual net income of $64M in fiscal 2025, representing a new all-time high.
Oramed Pharmaceuticals Inc. maintains industry-leading profitability with a gross margin of 0.7%, operating margin of -754.4%, and net margin of 3202.5%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including MNKD (-$24M net income, 1.7% margin), NRXP (-$25M net income, -2336.5% margin), PRAX (-$327M net income), ORMP has outperformed on profitability metrics. Compare ORMP vs MNKD →
ORMP Earnings vs Peers
Earnings metrics vs comparable public companies
ORMP Historical Earnings Data (2003–2025)
22 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $64M | +435.3% | -$15M | $1.50 | 3202.5% | -754.4% |
| 2024 | -$19M | -445.8% | -$13M | $-0.47 | - | - |
| 2023 | $6M | +114.6% | -$16M | $0.14 | 412.3% | -1176.8% |
| 2022 | -$38M | -69.8% | -$41M | $-0.97 | -1397.1% | -1502.0% |
| 2021 | -$22M | -93.2% | -$24M | $-0.78 | -822.7% | -896.2% |
| 2020 | -$12M | +19.8% | -$12M | $-0.56 | -424.8% | -433.8% |
| 2019 | -$14M | -12.8% | -$15M | $-0.82 | -531.1% | -541.3% |
| 2018 | -$13M | -21.4% | -$14M | $-0.86 | -519.7% | -552.3% |
| 2017 | -$10M | +4.4% | -$11M | $-0.79 | -426.7% | -438.6% |
| 2016 | -$11M | -51.6% | -$10M | $-0.87 | -1710.5% | -1561.6% |
| 2015 | -$7M | -27.0% | -$7M | $-0.67 | - | - |
| 2014 | -$6M | -34.6% | -$6M | $-0.62 | - | - |
| 2013 | -$4M | -26.5% | -$4M | $-0.59 | - | - |
| 2012 | -$3M | -114.2% | $3M | $-0.57 | -1815.1% | 1565.2% |
| 2011 | -$2M | +47.6% | -$2M | $-0.29 | -790.9% | -1233.6% |
| 2010 | -$3M | -7.9% | -$3M | $-0.62 | - | - |
| 2009 | -$3M | +0.3% | -$3M | $-0.58 | - | - |
| 2008 | -$3M | +14.4% | -$3M | $-0.68 | - | - |
| 2007 | -$3M | -680.6% | -$3M | $-0.92 | - | - |
| 2006 | $-414,576 | -805.6% | $-412,883 | $-0.15 | - | - |
| 2005 | $-45,781 | +8.4% | $-44,808 | $-0.01 | - | - |
| 2003 | $-50,000 | - | $-50,000 | $-0.00 | - | - |
Download Data
Export ORMP earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
23+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ORMP — Frequently Asked Questions
Quick answers to the most common questions about buying ORMP stock.
What is ORMP earnings per share (EPS)?
ORMP trailing twelve-month (TTM) diluted EPS is $2.62, reflecting +419.1% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2003 to 2025 is available in the table on this page.
What is Oramed Pharmaceuticals Inc.'s net income?
Oramed Pharmaceuticals Inc. (ORMP) trailing twelve-month net income is $110M as of 2025. Earnings grew +419.1% year-over-year.
Is ORMP profitable?
Yes, ORMP is profitable with a TTM net income of $110M and a net profit margin of +3202.5%.
What is ORMP's earnings growth rate?
ORMP compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2003 to 2025.
What are ORMP's profit margins?
Oramed Pharmaceuticals Inc. net profit margin is +3202.5%, operating margin is -754.4%, and gross margin is +0.7%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +37.1%.
Is ORMP growing earnings?
Yes, ORMP earnings are accelerating — EPS growth of +419.1% exceeds the 5-year CAGR of N/A. TTM net income reached $110M. Earnings momentum is strengthening.
What was ORMP's best earnings year?
Oramed Pharmaceuticals Inc.'s highest annual net income on record is $64M, achieved in fiscal year 2025. Earnings history on this page spans 2003 to 2025 and includes all annual and quarterly figures.
What were ORMP's earnings last quarter?
ORMP's most recent reported quarter was Q1 2026. Net income was $38M with diluted EPS of $0.91. For a full breakdown of all quarters, see the quarterly earnings table on this page.